For inquiries or customized services, please reach us at pr@pharmaceutical-era.com
Immorta Bio, Inc., a clinical-stage biotechnology company developing therapies to restore youthful biology, announced new laboratory findings involving SenoMune™-0257, its investigational nine-amino-acid...
Sonic Incytes Medical Corp., developer of the Velacur™ point-of-care liver assessment platform, announced a multi-year partnership with Madrigal Pharmaceuticals, Inc. a biopharmaceutical company...
Swisslog Healthcare, a global industry leader of pharmacy and transport automation solutions, introduces the Allegro™ refrigeration module and an expanded Tempo software platform, marking the most...
Fonseca Biosciences, a specialty pharmaceutical company commercializing clinically differentiated pharmaceutical products, announced that the pooled results from two Phase 3 clinical trials...
Thermo Fisher Scientific, the world leader in serving science, announced the Gibco™ VaxEvo™ CD 293 Medium, a chemically defined and animal origin-free medium designed to support suspension HEK293...
GLP-1 medications are taking a growing share of employer pharmacy budgets, pushing self-funded plans to look beyond negotiated discounts and examine who qualifies for treatment, where medications...
A drug nearing patent expiration may seem like relief from high prices, but lower-cost competition can still take years to reach the market.
Seawolf Therapeutics announced its emergence from stealth, having raised $100 million to transform patient outcomes through the use of its proprietary DNA delivery...
Estrella Immunopharma, Inc. a clinical-stage biopharmaceutical company developing next-generation ARTEMIS T-cell therapies for cancer and autoimmune diseases, highlighted preclinical findings from an...
Bruker Corporation announced that its Board of Directors is adding Eicke Latz, MD PhD to serve on its board of directors, effective as of January 1, 2027. Dr. Latz is an internationally recognized...
CS Analytical (CSA), doing business as Raw Material Analytical (RMA), a cGMP laboratory dedicated to advancing product quality and patient safety, today announced that it is set to offer analytical...
VectorY Therapeutics (“VectorY”), a clinical-stage biotechnology company pioneering vectorized antibody therapies for neurodegenerative diseases, today announced €74.5 million ($83.5 million) in new...